Discounted Cash Flow (DCF) Analysis Levered

Unity Biotechnology, Inc. (UBX)

$1.31

+0.46 (+54.10%)
All numbers are in Millions, Currency in USD

Free Cash Flow

Year
A/P
2017
Actual
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 1.38---------
Revenue (%)
Operating Cash Flow -38.36---------
Operating Cash Flow (%)
Capital Expenditure -1.69---------
Capital Expenditure (%)
Free Cash Flow -40.05---------

Weighted Average Cost Of Capital

Share price $ 1.31
Beta 0.638
Diluted Shares Outstanding 55.82
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt -0.01%
Risk-Free Rate
Market Risk Premium
Cost of Equity 5.862
Total Debt 51.56
Total Equity 73.12
Total Capital 124.68
Debt Weighting 41.35
Equity Weighting 58.65
Wacc

Build Up Free Cash Flow

Year
A/P
2017
Actual
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 1.38---------
Operating Cash Flow -38.36---------
Capital Expenditure -1.69---------
Free Cash Flow -40.05---------
WACC
PV LFCF ---------
SUM PV LFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 3.43
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt 18.65
Equity Value -
Shares Outstanding 55.82
Equity Value Per Share -